<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606709</url>
  </required_header>
  <id_info>
    <org_study_id>11-168-1</org_study_id>
    <nct_id>NCT01606709</nct_id>
  </id_info>
  <brief_title>Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation</brief_title>
  <official_title>A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare gene expression profiles in endometrial biopsies
      during the window of implantation after triggers of oocyte maturation using GnRH agonist or
      hCG and compared with their natural cycles in order to identify genes that may be
      dysregulated in GnRH agonist-triggered cycles.

      The investigators also intend to evaluate patients feeling of well being and physical quality
      of life after GnRH agonist trigger compared with hCG trigger.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian
      hyperstimulation (COH) which may result in significant morbidity and rarely mortality as well
      as significant financial and psychological distress. The use of a GnRH agonist for induction
      of final oocyte maturation in ovarian stimulation cycles utilizing GnRH antagonist for
      pituitary suppression has proven to be an effective method of preventing the risk of OHSS
      development.

      Unfortunately, some studies, but not all, have also reported lower pregnancy rates in these
      cycles as compared to cycles using hCG trigger and this has been attributed to possible
      impaired endometrial receptivity.

      The investigators intend to obtain endometrial biopsies collected from the same subject in a
      natural cycle and then a biopsy during either a GnRH agonist or hCG triggered stimulation.
      Expression profiles of mRNAs will first be screened using microarray technology. Relative
      levels of specific mRNAs that display altered expression in the GnRH-triggered samples, as
      assayed by microarray, will then be confirmed by real-time, quantitative reverse
      transcription/polymerase chain reaction (Q-PCR). The investigators shall also evaluate
      patients feeling of well being and physical quality of life after GnRH agonist trigger
      compared with hCG trigger.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult to recruit patients
  </why_stopped>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial Gene Expression Profile</measure>
    <time_frame>7 days after trigger of oocyte maturation</time_frame>
    <description>Microarray of gene expression in the midluteal phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey After Ovarian Stimulation and GnRHa or hCG Trigger</measure>
    <time_frame>At baseline and up to 7 days after trigger of oocyte maturation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Endometrial Receptivity</condition>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>GnRH agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction of oocyte maturation with GnRH agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction of oocyte maturation with hCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>GnRH agonist 1mg one dose</description>
    <arm_group_label>GnRH agonist trigger</arm_group_label>
    <other_name>leuprolide acetate,</other_name>
    <other_name>lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>5,000 IU one dose</description>
    <arm_group_label>hCG trigger</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Oocyte donors

          -  Ages between 21 and 33

          -  Normal baseline serum FSH &lt; 10mIU/mL

        Exclusion Criteria:

          -  Hypothalamic dysfunction

          -  Smokers

          -  Baseline serum FSH â‰¥ 10mIU/mL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>33 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Engmann, MD, MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCHC Division of Reproductive Endocrinology</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 19, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>October 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2018</results_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Lawrence Engmann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>GnRHa trigger</keyword>
  <keyword>endometrial gene profile</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GnRH Agonist Trigger</title>
          <description>Induction of oocyte maturation with GnRH agonist
GnRH agonist: GnRH agonist 1mg one dose</description>
        </group>
        <group group_id="P2">
          <title>hCG Trigger</title>
          <description>Induction of oocyte maturation with hCG
hCG: 5,000 IU one dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GnRH Agonist Trigger</title>
          <description>Induction of oocyte maturation with GnRH agonist
GnRH agonist: GnRH agonist 1mg one dose</description>
        </group>
        <group group_id="B2">
          <title>hCG Trigger</title>
          <description>Induction of oocyte maturation with hCG
hCG: 5,000 IU one dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Gene Expression Profile</title>
        <description>Microarray of gene expression in the midluteal phase</description>
        <time_frame>7 days after trigger of oocyte maturation</time_frame>
        <population>Inadequate RNA quality to completely analyze gene expression</population>
        <group_list>
          <group group_id="O1">
            <title>GnRH Agonist Trigger</title>
            <description>Induction of oocyte maturation with GnRH agonist
GnRH agonist: GnRH agonist 1mg one dose</description>
          </group>
          <group group_id="O2">
            <title>hCG Trigger</title>
            <description>Induction of oocyte maturation with hCG
hCG: 5,000 IU one dose</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Gene Expression Profile</title>
          <description>Microarray of gene expression in the midluteal phase</description>
          <population>Inadequate RNA quality to completely analyze gene expression</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey After Ovarian Stimulation and GnRHa or hCG Trigger</title>
        <time_frame>At baseline and up to 7 days after trigger of oocyte maturation</time_frame>
        <population>Too few patients completed survey to meaningfully analyze data</population>
        <group_list>
          <group group_id="O1">
            <title>GnRH Agonist Trigger</title>
            <description>Induction of oocyte maturation with GnRH agonist
GnRH agonist: GnRH agonist 1mg one dose</description>
          </group>
          <group group_id="O2">
            <title>hCG Trigger</title>
            <description>Induction of oocyte maturation with hCG
hCG: 5,000 IU one dose</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey After Ovarian Stimulation and GnRHa or hCG Trigger</title>
          <population>Too few patients completed survey to meaningfully analyze data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks for each patient</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GnRH Agonist Trigger</title>
          <description>Induction of oocyte maturation with GnRH agonist
GnRH agonist: GnRH agonist 1mg one dose</description>
        </group>
        <group group_id="E2">
          <title>hCG Trigger</title>
          <description>Induction of oocyte maturation with hCG
hCG: 5,000 IU one dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Engmann</name_or_title>
      <organization>UConnHealth</organization>
      <phone>8605258283</phone>
      <email>lengmann@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

